Todd Shapiro is the CEO of Red Light Holland ($TRIP, $TRUFF), the only publicly traded company focused on recreational psychedelics.    In this episode of The Integration Conversation, Todd explains the history of Red Light Holland, speculates on timelines for when Red Light Holland will be able to sell in the US, and tells us about Red Light Holland's foray into Virtual Reality and consumer products like the Wisdom Truffle.  

And of course, we ask the big question:  Is Red Light Holland Undervalued?   

---

❤️ Invest in Brom's Psychedelic Venture Capital Fund: 

https://www.empath.vc

📺Watch on YouTube:

https://youtu.be/1OzpNIQDkyI

⚠️Disclaimer: 

This content is not financial advice. Brom holds shares in Red Light Holland

Negev Capital is a VC fund focused on psychedelic medicine.  

In this episode of The Integration Conversation, Ken Belotsky and Stuart Seidman tell us about Negev's founding, its strategy, and what it's like to run a venture fund in the psychedelics space.    

❤️ Help us fund the future of psychedelic medicine at Empath Ventures: https://www.empath.vc 

⭐️ Become an Integration Insider and get early access to episodes: https://patreon.com/theintegrationco 

🐦 brom on twitter:  

https://twitter.com/therealbrom 

🎇 Clips and other stuff on Instagram:  

https://instagram.com/theintegrationco 

⏰ Timestamps:  

0:45 - Ken & Stuart’s backgrounds  

6:00 - what is it like raising money for a Psychedelic Venture Fund?  

14:00 - what is Negev’s focus?   

19:30 - how do you do due diligence?   

23:30 - do novel psychedelics replace the classic psychedelics in the long run?   

26:30 - what are the developing trends in psychedelics?   

37:30 - is there too much capital in the space?

Jack Swain is the Head of Clinical Operations at Mindbloom, the world's largest telemedicine based ketamine clinic.    In this episode of The Integration Conversation, Jack talks about what it's like to be involved in a rapidly growing psychedelic startup, the differences between in-clinic and telemedicine based ketamine therapy, and how Mindbloom will scale to other psychedelic drugs like psilocybin and MDMA.

❤️ Help us fund the future of psychedelic medicine at Empath Ventures: 

https://www.empath.vc 

📺 Watch on YouTube: 

https://youtu.be/HskAmw27a-M 

⭐️ Become an Integration Insider and get early access to episodes: 

https://patreon.com/theintegrationco 

🐦 brom on twitter:  

https://twitter.com/therealbrom 

🎇 Clips and other stuff on Instagram:  

https://instagram.com/theintegrationco  

disclaimer:  this is not financial advice

Paul Kohlhaas is the cofounder of Molecule ( https://molecule.to/ ) a collaborative platform where stakeholders in drug development work together to accelerate the process of bringing novel therapeutics to patients.  He is also the co-initiator of VitaDAO ( https://www.vitadao.com/ ), a decentralized collective funding early stage longevity research.  In this episode we discuss the exciting intersection of crypto and biotech, and how DAOs might replace some of the traditional funding mechanisms of scientific research.      

❤️ Help us fund the future of psychedelic medicine at Empath Ventures: https://www.empath.vc

Bruce Linton is a legend in the cannabis and psychedelics industries.  He was the CEO of the world's largest cannabis company (Canopy Growth), was the first investor in MindMed, and is Chairman of the Advisory Board at Red Light Holland.   

Bruce joins The Integration Conversation to answer questions like:  

And more!   

Plus, Brom and Bruce talk about Empath Ventures.  

❤️ Help us fund the future of psychedelic medicine at Empath Ventures: 

https://www.empath.vc 

⭐️ Become an Integration Insider and get early access to episodes: 

https://patreon.com/theintegrationco 

🐦 brom on twitter:  

https://twitter.com/therealbrom 

🎇 Clips and other stuff on Instagram:  

https://instagram.com/theintegrationco

Disclaimer / Disclosure:  This is not financial advice.  Brom owns shares in MindMed, Red Light Holland and other psychedelics stocks. 

🍄 Bright Minds Bio is a psychedelics research company focused on novel  psychedelics with shorter trip times and lower risk than traditional  psychedelics.  In this episode of The Integration Conversation, we  discuss the risk of traditional psychedelics, what a 5HT2C agonist is,  Bright Mind's NASDAQ Uplisting, and discuss why Bright Minds might be  undervalued relative to its peers.     

⭐️ Become an Integration Insider and get early access to episodes: 

https://patreon.com/theintegrationco  

🎧 Listen on Spotify and other podcast platforms:  

https://anchor.fm/theintegrationco  

🐦 brom on twitter:  

https://twitter.com/therealbrom  

🎇 Clips and other stuff on Instagram:  

https://instagram.com/theintegrationco  

💌 Email:   

[email protected]   

⏰ Timestamps:  

Disclaimer: This video is not financial advice. Brom holds shares in Bright Minds.

🍄 Josh Bartch is the CEO of Mydecine Innovations Group, a psychedelics company that is researching naturally sourced psychedelic therapeutics targeting PTSD and smoking cessation.  In this episode of The Integration Conversation, Josh joins us for a full hour and tells us about Mydecine's clinical trials, its research on functional mushrooms, and makes his pitch for why Mydecine is undervalued relative to its peers.    

Questions we answer: 

🔥 Invest in Psychedelic Startups with Us 🔥 

go to https://theintegration.co and click on "invest in psychedelic startups"  

The Integration Conversation is a podcast that covers the emerging psychedelics industry from a business perspective, and aims to be your number 1 resource for investing in psychedelics,  psychedelic investing and psychedelic business.  

⛓ All our links:  

https://theintegration.co 

📝 My notes on psychedelic investing:  

https://brompersonal.s3-us-west-2.amazonaws.com/assets/broms-notes-psychedelic-investing.pdf   

🎧 Listen on Spotify and other podcast platforms:  

https://anchor.fm/theintegrationco 

🐦 brom on twitter:  

https://twitter.com/therealbrom 

🎇 Clips and other stuff on Instagram:  

https://instagram.com/theintegrationco  

⏰ Timestamps: 

Disclaimer: This video is not financial advice. Brom holds shares in Mydecine and other psychedelic stocks.

What exactly is psychedelic therapy, and what does the research on  psychedelic therapy tell us about its effectiveness?  

In this episode of  The Integration Conversation, Brom provides a description of what  exactly happens during psychedelic therapy, and then goes over the three  most compelling clinical research papers on psychedelic therapy.

Learn about how MDMA can treat Post Traumatic Stress Disorder,  psilocybin can treat depression, and how psilocybin stacks up against  SSRIs like Lexapro.   

👇 studies mentioned in this video    

MDMA for PTSD  https://www.nature.com/articles/s41591-021-01336-3  

Trial of Psilocybin versus Escitalopram for Depression 

https://www.nejm.org/doi/full/10.1056/NEJMoa2032994  

Psilocybin to treat Depression and Anxiety in Cancer patients 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367557/  

Psilocybin for smoking Cessation  

https://files.csp.org/Psilocybin/Johnson2017Smoking.pdf  

Ibogaine for Opioid Dependence  

https://pubmed.ncbi.nlm.nih.gov/28402682/     

In this episode of The Integration Conversion, brom give a broad overview of the psychedelic investing landspace, and addresses come common misconceptions about investing in psychedelics.   

Topics Include:  

⏰ Timestamps: 

I'm experimenting with a weekly livestream format where I respond to  short psychedelic articles / topics that don't warrant an entire video.   Plus I interact with the viewers and answer their questions about any  psychedelic topics.